| 000 | 02550 a2200745 4500 | ||
|---|---|---|---|
| 005 | 20250514214735.0 | ||
| 264 | 0 | _c20050919 | |
| 008 | 200509s 0 0 eng d | ||
| 022 | _a1527-9995 | ||
| 024 | 7 |
_a10.1016/j.urology.2004.08.041 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aEfstathiou, E | |
| 245 | 0 | 0 |
_aCombination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment. _h[electronic resource] |
| 260 |
_bUrology _cJan 2005 |
||
| 300 |
_a126-30 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAdenocarcinoma _xblood |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAlopecia _xchemically induced |
| 650 | 0 | 4 |
_aAndrogen Antagonists _xtherapeutic use |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Hormonal _xtherapeutic use |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects |
| 650 | 0 | 4 |
_aBiomarkers, Tumor _xblood |
| 650 | 0 | 4 |
_aBone Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aCombined Modality Therapy |
| 650 | 0 | 4 |
_aDiphosphonates _xadministration & dosage |
| 650 | 0 | 4 | _aDisease Progression |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 | _aDocetaxel |
| 650 | 0 | 4 | _aDrug Resistance, Neoplasm |
| 650 | 0 | 4 |
_aEstramustine _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImidazoles _xadministration & dosage |
| 650 | 0 | 4 | _aLife Tables |
| 650 | 0 | 4 |
_aLiver Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aLung Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aLymphatic Metastasis |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeoplasm Proteins _xblood |
| 650 | 0 | 4 |
_aNeutropenia _xchemically induced |
| 650 | 0 | 4 | _aOrchiectomy |
| 650 | 0 | 4 |
_aPain _xdrug therapy |
| 650 | 0 | 4 | _aPalliative Care |
| 650 | 0 | 4 |
_aProstate-Specific Antigen _xblood |
| 650 | 0 | 4 |
_aProstatic Neoplasms _xblood |
| 650 | 0 | 4 | _aRadiotherapy, High-Energy |
| 650 | 0 | 4 | _aRemission Induction |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 |
_aTaxoids _xadministration & dosage |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aZoledronic Acid |
| 700 | 1 | _aBozas, G | |
| 700 | 1 | _aKostakopoulos, A | |
| 700 | 1 | _aKastritis, E | |
| 700 | 1 | _aDeliveliotis, C | |
| 700 | 1 | _aAntoniou, N | |
| 700 | 1 | _aSkarlos, D | |
| 700 | 1 | _aPapadimitriou, C | |
| 700 | 1 | _aDimopoulos, M A | |
| 700 | 1 | _aBamias, A | |
| 773 | 0 |
_tUrology _gvol. 65 _gno. 1 _gp. 126-30 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.urology.2004.08.041 _zAvailable from publisher's website |
| 999 |
_c15346365 _d15346365 |
||